Ligand id: 7979

Name: dinutuximab

No information available.
Summary of Clinical Use
Dinutuximab is in Phase III clinical trials for neuroblastoma. Click here to link to ClinicalTrials.gov's listing of Phase III dinutuximab trials.
In March 2015, the US FDA approved dinutuximab as a component of a multiagent, multimodality therapy (antibody + granulocyte-macrophage colony-stimulating factor (GM-CSF) + interleukin-2 (IL-2) + 13-cis-retinoic acid (isotretinoin)) for paediatric patients with high-risk neuroblastoma.
In Europe, the antibody has been remanufactured (and referred to as dinutuximab beta or ch14.18/CHO) and is being evaluated in a complex multi-factorial Phase III clinical trial in high risk pediatric neuroblastoma patients (NCT01704716).
Mechanism Of Action and Pharmacodynamic Effects
Ganglioside GD2 [2] is highly expressed on neuroectoderm-derived tumours and sarcomas, including neuroblastoma, retinoblastoma, melanoma and small cell lung cancer. In normal tissue GD2 expression is restricted to the brain making it inaccessible to circulating antibodies. This makes tumour GD2 an ideal target for immunotherapy [1]. Dinutuximab binds to GD2 and induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against GD2-expressing tumour cells [3].